Category Archives: R&D

Why do new medicines cost so much, and what can we do about it?

  The cost of new drugs is putting increasing pressure on people in both rich and poor countries. We explain why it’s a burning issue by Sarah Boseley Health editor Why does it matter what medicines cost? If you are lucky enough … Continue reading

Posted in Doha Declaration, Patent, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Less than four percent of private investment in health R&D targets the developing world

by Liz Sablich, Brookings  A recent report published by the Brookings Private Sector Global Health R&D Project found that the private sector devotes at least $159.9 billion to investments related to health research and development (R&D) annually. That total includes $156.7 billion from … Continue reading

Posted in R&D, Uncategorized | Leave a comment

Why do new medicines cost so much, and what can we do about it? The cost of new drugs is putting increasing pressure on people in both rich and poor countries. Sarah Boseley explains why it’s a burning issue

Source: The Guardian|April 09, 2018 Why does it matter what medicines cost? If you are lucky enough to live in a country with comprehensive state-funded healthcare, such as the UK, you probably have no idea how much medicines really cost. … Continue reading

Posted in Access to Medecines, Access to Medicins, Drug prices, IP Rights, Patent, Pricing, R&D | Leave a comment

Moment of truth for global TB response

On Thursday 16 November 2017, Russian president Vladimir Putin told a hall full of health ministers in Moscow that TB is a “serious problem”, and said, “I am confident that the only way we can stand up against this truly global threat … Continue reading

Posted in BRICS, R&D, Tuberculosis (TB), Uncategorized | Leave a comment

Patient commentary: the current model has failed

Source: BMJ The cost of cancer drugs is skyrocketing: prices of cancer drugs increased by 10% every year between 1995 and 2013.1 More and more we’re seeing cancer drugs being priced off the NHS—as is the case with secondary breast cancer … Continue reading

Posted in Cancer, Drug prices, R&D, Uncategorized | Leave a comment

Pharmaceutical Pricing Hostages

By Ellen t’ Hoen, Medicines Law & Policy Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring announced it will no longer provide Respreeza (human alpha1-proteinase inhibitor), … Continue reading

Posted in R&D, Uncategorized | Leave a comment

UACT ASKS CEOS FOR TRANSPARENCY ON CAR T TREATMENTS

Today, UACT submitted letters to the CEOs of three major pharmaceutical companies currently developing chimeric antigen receptor T-cell (CAR T) technologies.  UACT asked the leaders of Novartis, Gilead Sciences, and Juno Therapeutics to address questions regarding research and development (R&D) … Continue reading

Posted in Cancer, Drug prices, Gene Therapy, Patent, R&D, Uncategorized | Leave a comment